Pursuant to this certificate, the USPTO has extended the term of US patent No. 5,861,379 (tesamorelin composition of matter patent) by five years. This patent was originally set to expire in May 2015 and is now set to expire in May 2020.
"We are happy to see that the determination made by the USPTO in granting a five-year term extension is the same as the one we made when we applied for this patent term extension more than three years ago.
The combination of this five-year term extension on our main patent with our patents covering the use of tesamorelin for the treatment of HIV-associated lipodystrophy set to expire in 2023 should add value to our EGRIFTA asset and benefit our shareholders", said Mr. Luc Tanguay, President and CEO, Theratechnologies Inc.
Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and improved quality of life.